Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | ENPEP | Q07075 | 9/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | FPR2 | P25090 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25460023 | 0.94 | ALDH1A1 (0.46) | ALDH1A1ENPEPL3MBTL1 | |
| SCHEMBL31720964 | 0.91 | ENPEP (0.44) | ALDH1A1ENPEP | |
| SCHEMBL30390127 | 0.90 | PDCD1LG2 (0.49) | ALDH1A1ENPEPPDCD1LG2CD274 | |
| SCHEMBL30494692 | 0.89 | ALDH1A1 (0.53) | ALDH1A1ENPEPL3MBTL1 | |
| SCHEMBL30799474 | 0.89 | ALDH1A1 (0.53) | ALDH1A1ENPEPL3MBTL1 | |
| SCHEMBL3779195 | 0.89 | ALDH1A1 (0.53) | ALDH1A1ENPEPL3MBTL1 | |
| SCHEMBL30494638 | 0.89 | ALDH1A1 (0.53) | ALDH1A1ENPEPL3MBTL1 | |
| SCHEMBL3779192 | 0.89 | ALDH1A1 (0.53) | ALDH1A1ENPEPL3MBTL1 | |
| SCHEMBL7760297 | 0.89 | ALDH1A1 (0.53) | ALDH1A1ENPEPL3MBTL1 | |
| SCHEMBL31696945 | 0.88 | MME (0.49) | ENPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612617-B2 | Mitochondrial genome editing methods | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2026-04-28 | — | — | US | disclosed |
| US-12584144-B2 | Universal donor cells | CRISPR THERAPEUTICS AG (CH) | 2026-03-24 | — | — | US | disclosed |
| US-20260078414-A1 | Materials and Methods for Treatment of Pain Related Disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-03-19 | — | — | US | disclosed |
| US-12577582-B2 | Universal donor cells | CRISPR THERAPEUTICS AG (CH) | 2026-03-17 | — | — | US | disclosed |
| US-20260071238-A1 | MATERIALS AND PROCESSES FOR ENGINEERING HYPOIMMUNOGENICITY | JANSSEN BIOTECH INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260071189-A1 | BIOMATERIALS AND PROCESSES FOR IMMUNE SYNAPSE MODULATION OF HYPOIMMUNOGENICITY | JANSSEN BIOTECH INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12559726-B2 | Universal donor cells | CRISPR THERAPEUTICS AG (CH) | 2026-02-24 | — | — | US | disclosed |
| EP-3481857-B1 | MATERIALS AND METHODS FOR TREATMENT OF PAIN RELATED DISORDERS | VERTEX PHARMA (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20250376698-A1 | COMPOSITIONS AND METHODS FOR PROMOTING LIVER REGENERATION BY GENE EDITING IN METABOLIC LIVER DISEASE | DUKE UNIVERSITY | 2025-12-11 | — | — | US | disclosed |
| US-12492388-B2 | Materials and methods for treatment of hemoglobinopathies | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-12-09 | — | — | US | disclosed |
| US-20220107328-A1 | METHODS OF TREATING LIVER DISEASES | CAMP4 THERAPEUTICS CORPORATION | 2022-04-07 | — | — | US | disclosed |
| WO-2022061166-A1 | COMPOSITIONS AND METHODS FOR DETECTION OF A NUCLEIC ACID | MAMMOTH BIOSCIENCES, INC. (US) | 2022-03-24 | — | — | WO | disclosed |
| US-20220080055-A9 | COMPOSITIONS AND METHODS FOR GENE EDITING FOR HEMOPHILIA A | BAYER HEALTHCARE LLC | 2022-03-17 | — | — | US | disclosed |
| US-20220081680-A1 | MATERIALS AND METHODS FOR TREATMENT OF AUTOSOMAL DOMINANT CONE-ROD DYSTROPHY | BAYER HEALTHCARE LLC | 2022-03-17 | — | — | US | disclosed |
| EP-3967758-A1 | MATERIALS AND METHODS FOR TREATMENT OF ALPHA-1 ANTITRYPSIN DEFICIENCY | CRISPR Therapeutics AG (CH) | 2022-03-16 | — | — | EP | disclosed |
| US-11268077-B2 | Materials and methods for treatment of hemoglobinopathies | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-03-08 | — | — | US | disclosed |
| US-11266655-B2 | Methods and compositions for treating urea cycle disorders | CAMP4 THERAPEUTICS CORPORATION (US) | 2022-03-08 | — | — | US | disclosed |
| US-20220064667-A1 | UNIVERSAL DONOR CELLS | CRISPR THERAPEUTICS AG (CH) | 2022-03-03 | — | — | US | disclosed |
| US-20220049247-A1 | MATERIALS AND METHODS FOR TREATMENT OF USHER SYNDROME TYPE 2A AND/OR NON-SYNDROMIC AUTOSOMAL RECESSIVE RETINITIS PIGMENTOSA (ARRP) | CRISPR THERAPEUTICS AG (CH) | 2022-02-17 | — | — | US | disclosed |
| US-20220047722-A1 | MATERIALS AND METHODS FOR TREATMENT OF SPINOCEREBELLAR ATAXIA TYPE 1 (SCA1) AND OTHER SPINOCEREBELLAR ATAXIA TYPE 1 PROTEIN (ATXN1) GENE RELATED CONDITIONS OR DISORDERS | CRISPR THERAPEUTICS AG (CH) | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260071189-A1 | BIOMATERIALS AND PROCESSES FOR IMMUNE SYNAPSE MODULATION OF HYPOIMMUNOGENICITY | CD58, CD59, B2M | ALDH1A1 3660/4885ENPEP 2857/4885L3MBTL1 339/4885 |
| US-20220107328-A1 | METHODS OF TREATING LIVER DISEASES | PNPLA2, LIPC, PNLIP | ALDH1A1 505/4885ENPEP 259/4885L3MBTL1 1970/4885 |
| US-12584144-B2 | Universal donor cells | L1CAM, MICA, B2M | ALDH1A1 340/4885ENPEP 2638/4885L3MBTL1 102/4885 |
| US-20260071238-A1 | MATERIALS AND PROCESSES FOR ENGINEERING HYPOIMMUNOGENICITY | B2M, CD58, CBX8 | ALDH1A1 2622/4885ENPEP 2574/4885L3MBTL1 212/4885 |
| US-12612617-B2 | Mitochondrial genome editing methods | SSBP1, POLRMT, TFAM | ALDH1A1 3626/4885ENPEP 1434/4885L3MBTL1 284/4885 |
| US-12577582-B2 | Universal donor cells | L1CAM, MICA, PDCD1LG2 | ALDH1A1 527/4885ENPEP 2109/4885L3MBTL1 256/4885 |
| US-20260078414-A1 | Materials and Methods for Treatment of Pain Related Disorders | SCN9A, SCN7A, SCN8A | ALDH1A1 1780/4885ENPEP 4561/4885L3MBTL1 368/4885 |
| US-12559726-B2 | Universal donor cells | HLA-DRB1, TMX1, TAP2 | ALDH1A1 1320/4885ENPEP 1436/4885L3MBTL1 459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.